AstraZeneca is a science-driven biopharmaceutical company pushing the boundaries to deliver life-changing drugs.
It has more than 800 employees in Canada, dedicated to the research, development, and commercialization of innovative drugs. AstraZeneca Canada was recently awarded the role of a global center for clinical studies in oncology and immuno-oncology. We are currently conducting leading-edge clinical studies in oncology in lung cancer, head, and neck cancer.
We are focusing our skills and resources on the development of innovative drugs in three priority areas: 1) Cardiovascular, Renal and Metabolic Diseases (CVRM); 2) Oncology; 3) Respiratory, Inflammation and Autoimmunity.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2019, the company invested $51.8 million in research and development in Canada. Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1000 people in Canada and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. For further information, please consult www.novartis.ca.
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies.
We strive to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines. Our diverse portfolio offers a broad range of benefits and solutions to meet the needs of Canadians.
Pfizer’s innovative portfolio focuses on the discovery and development of new medicines and vaccines. By focusing on the best science and patient experience, Pfizer’s leadership and significant investments support faster delivery of breakthrough medicines that can fulfill unmet needs.
Sandoz, a division of Novartis, is a pioneer and a global leader in biosimilars. We are proud of our “end to end” model which includes research, development, manufacturing and commercialization of our high-quality, affordable biologics. Sandoz has generated over 530 million patient days of experience world-wide; with 8 biosimilars* in the areas of Immunology, Oncology and Endocrinology, with an industry leading portfolio of future biosimilars. At Sandoz, we pride ourselves as being one company delivering both innovation and sustainability to the healthcare system in Canada.
VIATRIS is a new healthcare player committed to providing access to medicines, promoting the development of activities in a sustainable manner, and promoting collective expertise to improve patient care. Created in 2020, following the merger of Mylan and Upjohn, Viatris brings together excellent scientific, industrial, and logistical skills as well as proven regulatory, medical, and commercial expertise to provide quality drugs to patients where they need them and when they need it.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information, please visit www.ca.gsk.com.
We’re a company that takes on the toughest health challenges.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbviecanada on Twitter or find us on Facebook, LinkedIn and Instagram.
Apobiologix focuses its activities on the commercialization of biosimilars. Apobiologix’s biosimilar program is a natural extension of Apotex’s long-standing history of promoting access to affordable, high-quality medicines in Canada and around the world. We aim to transform access to affordable treatment through innovation, development and partnerships, in oncology and other areas.
At Apobiologix, we believe that invention is not the only form of innovation; we believe that health care professionals and patients deserve access to affordable treatments, without compromising on efficacy, quality and safety. Apobiologix is a pioneer and leader in the field of biosimilars in oncology in Canada. We offer you a filgrastim with short action as well as long action; Grastofil and Lapelga. Apobiologix offers a patient support program, the Answers program. It is an effective and fast program that helps access the drug for all patients.
At Eisai, everything we do is guided by a simple, yet transformative principle: patients and their families come first and we have a responsibility to listen to and learn from them. We call this human health care or hhc.
ONLY BY UNDERSTANDING A PATIENT’S REALITY CAN WE WORK TO BETTER SERVE THEIR NEEDS
We give our first thoughts to patients and their families, and to helping increase the benefits health care provides. Everyone at Eisai spends at least two to three days each year directly interacting with patients and learning about their experiences.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, cardiovascular disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information, visit www.amgen.ca and follow us on twitter @AmgenCanadaGM and on Facebook @AmgenCanada
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, producing drugs and vaccines for many of the most trying diseases in the world. Through our prescription drugs, vaccines, biologics, and animal health products, we collaborate with our customers and work in more than 140 countries to provide innovative health solutions. We are also demonstrating our determination to improve access to health care through broad policies, programs, and partnerships. Today, Merck remains at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world, including cancer, cardiometabolic diseases, emerging animal diseases, Alzheimer’s disease, and infectious diseases, including HIV and Ebola.
At Elvium Life Sciences, we seek to empower people to live better through science.
We are driven by a desire to be leaders in innovative life sciences and to provide our clients with treatment solutions that meet unmet medical needs.
Improving the health of Canadians is the reason for being of our commitment and our mobilization and our goal is to provide innovative drugs that are increasingly effective in the years to come.
AQCAMO seeks to improve the lives of cancer patients. To do so, we are dedicated to making oncology drugs more accessible to patients. With the help of our coordinators, we support and assist patients and their families by alleviating the financial burden caused by their cancer diagnosis to the best of our abilities.
We help patients and their families research, complete and submit their applications to the appropriate financial aid and support programs. In addition, we are committed to sharing knowledge and providing training and networking opportunities to all of our access coordinators.